HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesLinzagolix
Chemical structure of CAS 935283-04-8

Linzagolix

In Stock•Starting at $24 for 1 mg•Purity ≥ 98%
CAS No.935283-04-8
MDL No.N/A
MFC22H15F3N2O7S
MW508.40
InChI KeyBMAAMIIYNNPHAB-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$24In Stock
5 mg98%$36In Stock
10 mg98%$51In Stock
25 mg98%$124In Stock
50 mg98%$232In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.935283-04-8
Product NameLinzagolix

Biological Targets

GNRHR

Associated Conditions

Uterine leiomyoma·liver disease·uterine fibroid·leiomyoma·kidney disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC • Vol. 44, Issue 12 • 2022
PMID: 36368594DOI: 10.1016/j.jogc.2022.10.012

Oral gonadotropin-releasing hormone antagonists for treating endometriosis-associated pain: a systematic review and network meta-analysis.

Fertility and sterility • Vol. 118, Issue 6 • 2022
PMID: 36283862DOI: 10.1016/j.fertnstert.2022.08.856

Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.

Clinical and experimental pharmacology & physiology • Vol. 49, Issue 10 • 2022
PMID: 35690889DOI: 10.1111/1440-1681.13688

Linzagolix: First Approval.

Drugs • Vol. 82, Issue 12 • 2022
PMID: 35997940PMC: PMC9396591DOI: 10.1007/s40265-022-01753-9

Documentation

Similar Products